Andreessen Horowitz Partner Vijay Pande Steps Down from Bio + Health Role
After founding the a16z Bio + Health strategy at Andreessen Horowitz in 2014, Vijay Pande has announced that he will be stepping down from his role as a general partner. This news comes as a surprise to many in the industry, given Pande’s instrumental role in the firm’s success.
Under Pande’s leadership, a16z Bio + Health has raised four funds totaling nearly $3 billion each, with a recent $1.5 billion fund closing in 2022. However, the team is now shifting focus to a smaller $750 million fifth fund, as reported by The Wall Street Journal.
In January, a16z Bio + Health also announced the management of a $500 million biotech fund in partnership with pharmaceutical giant Eli Lilly, further solidifying their commitment to innovation in the healthcare space.
The focus of a16z Bio + Health is on backing digital health startups and companies that leverage AI, computation, and biology to drive advancements in healthcare.
Some of Pande’s notable investments include Devoted Health, a provider of individualized medical plans; Function Health, a startup specializing in personalized lab testing; and Freenome, a company dedicated to early cancer detection through blood draws. Prior to his venture capital career, Pande served as a professor at Stanford University in the fields of chemistry, structural biology, and computer science.
Despite Pande’s departure, the a16z Bio + Health team remains strong with partners Jorge Conde, Julie Yoo, and Vineeta Agarwala continuing to lead the charge in shaping the future of healthcare innovation.
